K. High

Molecular Biology · 2000–2018

A researcher in the Science corpus: 11 papers; trusts 6 researchers and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 94 citations into it; #11,262 of 17,773 by trust here, #3,712 by citations
• Genetics — 77 citations into it; #4,706 of 6,854 by trust here, #835 by citations
• Oncology — 41 citations into it
• Immunology — 16 citations into it
• Infectious Diseases — 6 citations into it
• Biomedical Engineering — 5 citations into it

Whom K. High trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. L. Naldini
2. F. Mingozzi
3. R. Brentjens
4. Michel Sadelain
5. I. Rivière
6. M. Kay

Who trusts K. High overall

1. C. Dunbar

Papers from K. High's perspective

Ordered by how strongly the researchers K. High trusts endorse each paper. Same corpus, a different order for every researcher.

1. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia (New England Journal of Medicine)
2. Multiplex Genome Engineering Using CRISPR/Cas Systems
3. Breaking the Code of DNA Binding Specificity of TAL-Type III Effectors (Science)
4. RNA-Guided Human Genome Engineering via Cas9
5. A Simple Cipher Governs DNA Recognition by TAL Effectors (Science)
6. Targeting DNA Double-Strand Breaks with TAL Effector Nucleases (Genetics)
7. A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
8. CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes (Cell)
9. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. (Cell)
10. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia (Nature)

Their papers

• Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges (2011) — 832 citations
• Safety and efficacy of gene transfer for Leber's congenital amaurosis. (2008) — 2,123 citations
• Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector (2000) — 1,049 citations
• Immune responses to AAV vectors: overcoming barriers to successful gene therapy. (2013) — 901 citations
• Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. (2009) — 816 citations
• Gene therapy comes of age (2018) — 1,212 citations
• Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B (2011) — 1,797 citations
• Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant (2017) — 638 citations
• Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial (2017) — 1,349 citations
• Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B (2014) — 1,138 citations
• CD8+ T-cell responses to adeno-associated virus capsid in humans (2007) — 736 citations